VEOPOZ

This brand name is authorized in United States

Active ingredients

The drug VEOPOZ contains one active pharmaceutical ingredient (API):

1 Pozelimab UNII 0JJ21K6L2I - POZELIMAB
Pozelimab-bbfg is a human, monoclonal immunoglobulin G4^P (IgG4^P) antibody directed against the terminal complement protein C5 that inhibits terminal complement activation by blocking cleavage of C5 into C5a (anaphylatoxin) and C5b, thereby blocking the formation of the membrane-attack complex (C5b-C9, a structure mediating cell lysis). Read about Pozelimab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VEOPOZ Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: US	FDA, National Drug Code	Identifier(s): 61755-014

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.